Search Results - Geoffrey R Oxnard

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases by Aakash Desai, Lincoln W. Pasquina, Candice Nulsen, Rachel B. Keller-Evans, Douglas A. Mata, Hanna Tukachinsky, Geoffrey R. Oxnard

    Published in The Journal of Liquid Biopsy (2024-06-01)
    Get full text
    Article


  2. 2

    Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types by Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard

    Published in Journal for ImmunoTherapy of Cancer (2022-10-01)
    Get full text
    Article


  3. 3

    Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing by Nadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, Kim DeLeonardis, Lauren Hogan, Hanna Tukachinsky, Erica Gornstein, Geoffrey R. Oxnard, Kimberly McGregor, Rachel B. Keller

    Published in npj Precision Oncology (2023-08-01)
    Get full text
    Article


  4. 4

    Genomic landscape of 891 RET fusions detected across diverse solid tumor types by Vamsi Parimi, Khaled Tolba, Natalie Danziger, Zheng Kuang, Daokun Sun, Douglas I. Lin, Matthew C. Hiemenz, Alexa B. Schrock, Jeffrey S. Ross, Geoffrey R. Oxnard, Richard S. P. Huang

    Published in npj Precision Oncology (2023-01-01)
    Get full text
    Article


  5. 5

    Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis by David P Carbone, David Spigel, Jeffrey S Ross, Karthikeyan Murugesan, Gerald Li, Richard S P Huang, Ryon P Graf, Geoffrey R Oxnard, Alexa Schrock, Liangliang Zhang, Khaled Tolba, Jacob Sands

    Published in Journal for ImmunoTherapy of Cancer (2023-01-01)
    Get full text
    Article


  6. 6

    Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivol... by Jie He, David Fabrizio, Jonathan Baden, Parul Doshi, James Pratt, Lee A Albacker, Geoffrey R Oxnard, Gina Fusaro, Natallia Kalinava, Dean C Pavlick, Ericka M Ebot, Hanna Tukachinsky, George Green

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Get full text
    Article


  7. 7

    Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab by Maya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, Chang Xu, Jessica K. Lee, Lo‐Bin Chang, Russell W. Madison, Frank Lin, Eugene Hsu, Vipul Kumar Patel, Alexey Aleshin, Geoffrey R. Oxnard, John Simes, Halla Nimeiri, David M. Thomas

    Published in Molecular Oncology (2023-02-01)
    Get full text
    Article


  8. 8

    Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors by Jessica K. Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan S. Sokol, Sai-Hong Ignatius Ou, Zhen Shi

    Published in npj Precision Oncology (2022-12-01)
    Get full text
    Article


  9. 9

    Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN by Saori Mishima, Yoshiaki Nakamura, Hanna Tukachinsky, Hiroya Taniguchi, Shigenori Kadowaki, Ken Kato, Eiji Oki, Taroh Satoh, Daisuke Aoki, Kentaro Yamazaki, Taito Esaki, Makoto Ueno, Tomohiro Nishina, Yu Sunakawa, Tadamichi Denda, Hideaki Bando, Naomi Kuramoto, Satoshi Horasawa, Hikaru Abutani, Jessica K. Lee, Russell W. Madison, Geoffrey R. Oxnard, Takayuki Yoshino

    Published in The Journal of Liquid Biopsy (2023-09-01)
    Get full text
    Article


  10. 10

    Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

    Published in Journal for ImmunoTherapy of Cancer (2025-02-01)
    Get full text
    Article


Search Tools: